Gen AI for Healthcare

Secure AI for chart reviews, clinical decision support, clinical trial EHR screening, smart search over EHRs,and responses to patient queries

Give me patient's cardiac history

History of CAD with NSTEMI in Nov 2019 → PCI with DES to mid-LAD; HTN, HLD; paroxysmal atrial fibrillation diagnosed Feb 2023; no known heart failure.
Currently reports exertional chest tightness only with >3 flights of stairs, no rest pain, orthopnea, syncope, or edema; rare palpitations.
Last echo (Mar 2025) LVEF 55% with mild concentric LVH and no significant valvular disease; last stress test (Sep 2024) showed no inducible ischemia.
On aspirin 81 mg, atorvastatin 40 mg, metoprolol succinate 50 mg daily, losartan 50 mg daily, and apixaban 5 mg BID for AF; nonsmoker, BP typically ~128/78, LDL 68 mg/dL.

Streamline chart reviews

Instantly retrieve relevant information from medical records and lab/radiology results during patient visits.

For a 72-year-old with nonvalvular atrial fibrillation (CHA₂DS₂-VASc 4), CKD stage 3 (eGFR 42 mL/min/1.73 m²), and weight 78 kg, what anticoagulant and dose are appropriate?

Oral anticoagulation is indicated given CHA₂DS₂-VASc ≥2. A DOAC is preferred over warfarin; apixaban 5 mg twice daily is appropriate here, as dose reduction to 2.5 mg BID is only recommended if at least two are present: age ≥80, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. Screen for contraindications (active bleeding, recent intracranial hemorrhage, mechanical valve or moderate–severe mitral stenosis) and drug interactions before prescribing. Recheck renal function and adherence at least annually, counsel on bleeding precautions, and consider a PPI if there’s high GI bleed risk or concurrent dual antiplatelet therapy. [1]

Clinical Decision Support

Retrieve similar cases and get instant insights from internal and external knowledge sources to support informed decision making.

Inclusion: Age 18–85; metastatic NSCLC (adenocarcinoma); EGFR exon 19 del or L858R positive; ECOG 0–2; adequate organ function (eGFR ≥45, AST/ALT ≤2.5×ULN, platelets ≥100k); able to consent. Exclusion: Uncontrolled cardiac disease; QTc >480 ms; active infection; pregnancy; prior EGFR TKI use; strong CYP3A inhibitors; MRI contraindication.

ID	Age	EGFR status	ECOG	eGFR	Link
P-001	64	Ex19del +	1	62	see patient's EHR
P-002	81	L858R +	2	48	see patient's EHR
P-009	57	Ex19del +	0	74	see patient's EHR
P-010	72	L858R +	1	65	see patient's EHR
P-011	45	L858R +	2	90	see patient's EHR
P-012	68	Ex19del +	1	55	see patient's EHR
P-013	39	Ex19del +	0	83	see patient's EHR
P-014	76	L858R +	2	58	see patient's EHR
P-015	52	Ex19del +	1	71	see patient's EHR
P-016	63	L858R +	0	66	see patient's EHR

Research & Clinical Trials

Identify eligible patients based on complex criteria combining structured and unstructured data.

What are my latest lab results, and are any marked “high” or “low”?

Your most recent labs (collected on Aug 12, 2025) show normal blood counts and kidney/liver function.
Flagged results: fasting glucose 112 mg/dL (H) and triglycerides 210 mg/dL (H); values like hemoglobin 14.1 g/dL, creatinine 0.96 mg/dL (eGFR 92), and ALT 22 U/L are within the listed ranges.

Patient Engagement

Intelligent visit preparation, answers to patient questions, smart search across own health records.